Biotechnology News

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential...

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus...

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the...

AC Immune announces positive safety and immunogenicity results through week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for...

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001...

Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development -Interim CEO Dr. Bo Rode Hansen resumes role as member of...

LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based discovery platforms to transform drug development in oncology, fibrosis...

BRISTOL, United Kingdom, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics Ltd (‘Scarlet’), a biotech company developing red blood cell-based therapeutics, today announced that it has entered...

OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting